WaferiX

The company says the study unlocks Wafermine’s potential to address the global cancer pain market, estimated at US$5.5 bil.

New freeze-dry equipment will boost the production of its WaferiX wafers up to six times its current capacity.

iX Biopharma has partnered with China Resources Pharmaceutical Group to distribute products in China.

The biotech company could finally turn profitable in FY21 as revenue could be bumped up by as much as 250%, says the brokerage.

iX Biopharma says its intellectual property rights for its sublingual wafer technology is now secured in five continents.

iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolving sublingual sildenafil wafer for the treatment of male erectile dysfunction.

SINGAPORE (June 19): iX Biopharma says the Australia’s regulatory authority, Therapeutic Goods Administration (TGA), has given the go-ahead for the use of Wafesil to treat of male erectile dysfunction in the country.

SINGAPORE (Oct 23): Specialty pharmaceutical firm iX Biopharma announced Monday that it has secured a European patent for its WaferiX drug delivery technology.

SINGAPORE (Nov 21): Pharmaceutical company iX Biopharma announced that it has been granted a patent in South Africa for its WaferiX drug delivery technology. The patent will expire on Oct 26, 2030.

SINGAPORE (Oct 31): iX Biopharma announced that it has secured a Canadian patent for its WaferiX drug delivery technology.